Carrick Therapeutics has announced that it plans to establish business operations in Boston, Massachusetts, and the transition of leadership from Elaine Sullivan, based in Dublin, to Tim Pearson, based in Boston, Massachusetts.
“The board of directors has made the decision to expand company operations in Boston to access US capital markets and the tremendous talent pool to support the expected growth of Carrick. With this transition, we will continue operations in Dublin and the UK, while adding new capabilities in Boston,” said Dr George Golumbeski, chairman of the board.
He continued, “We are thankful for all that Elaine has done in taking Carrick from inception to a company with multiple clinical assets in such a short period of time, and I am delighted that we will continue to have Elaine drive the company forward as executive entrepreneur and advisor to the board of directors.”
Mr Pearson brings a track record of growing biotech companies from R&D stage through commercialisation, along with significant fund raising and strategic business development. He most recently held the position of executive vice president and chief financial officer for Tesaro, a public oncology-focused biopharmaceutical company acquired by GSK in January of 2019.
Prior to that, he was chief financial officer at Catalyst Health Solutions, a publicly held pharmacy benefit manager with over $5 billion in revenues until the company was acquired by SXC Health Solutions in 2012.
